Sep 19 2006, 4:20 PM EST
News source: Business Wire
-- Drug Repositioning Summit presents new methodologies for drug-indication discovery
-- Research experts discuss innovative technologies for stalled pharmaceutical pipelines
-- Summit offers tools for challenging business models and organization structure
Cambridge Healthtech Institute (CHI), leading organizer of conferences for life science professionals exclusively, announced today its first ever Drug Repositioning Summit, October 16-17, 2006 in Philadelphia, Pennsylvania. Gene Logic Inc., one of the sector's pioneers, is the Exclusive Sponsor of this event.
The Drug Repositioning Summit enables top pharmaceutical and biotechnology researchers and executives to review the latest technology information and innovations in drug discovery. This premier Drug Repositioning Summit offers a pre-conference workshop, presentations, and case studies from distinguished faculty and speakers including former Aventis worldwide head of research, Frank L. Douglas, Ph.D., M.D., now executive director, MIT Center for Biomedical Innovation, Massachusetts Institute of Technology. Organizations presenting at the Drug Repositioning Summit include Pfizer, Organon, and Johns Hopkins University School of Medicine.
"Finding new development paths for failed, stalled, or de-prioritized clinical-stage drug candidates enables pharmaceutical companies to discover new clinical solutions for the physicians and patients," said Phillips Kuhl, president of CHI. "The insights from this summit will define how different technologies and services can be used to find new indications and how pharmaceutical companies are reinvigorating stalled pipelines."
The Drug Repositioning Summit will be held at the Park Hyatt Hotel in Philadelphia. To gain more information, register for the conference or to download the brochure with workshop and presentation details visit www.healthtech.com or call 781-972-5400 or toll-free at 888-999-6288.
About Cambridge Healthtech Institute
CHI's renowned conferences are the underpinning for all our other information resources. Each year, CHI organizes over 80 conferences held throughout the US, including The Molecular Medicine Tri-Conference, Beyond Genome, PepTalk, World Pharmaceutical Congress and the new acquired Bio-IT World's Life Sciences Conference & Expo. The company strives to develop quality programs that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. Leading researchers and business experts from top pharmaceutical, biotech and academic organizations present their most current findings in a forum that features panel discussions and audience participation. Over the past 14 years, CHI has produced more than 600 conferences, attracting more than 50,000 attendees from around the world. In addition to CHI's vast conference portfolio, their media properties include Pharma DD and Bio-IT World.
Gene Logic Overview
Gene Logic technologies and services are used by many of the world's top pharmaceutical and biotechnology companies. Over 150 organizations and government agencies have benefited from Gene Logic's diverse portfolio of drug development services, enabling them to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. Gene Logic has drug repositioning programs in place with a number of pharmaceutical companies, including Pfizer, Roche, and Organon. Founded in 1994, Gene Logic is headquartered in Gaithersburg, Maryland, conducts additional research and development in facilities in Cambridge, Massachusetts, and has customer suppor
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
News
Articles
Blogs